Sero-efficacy of Vi-polysaccharide tetanus-toxoid typhoid conjugate vaccine (Typbar-TCV) by Voysey, M, Pollard, A

“…<strong>Conclusion</strong> This is the first field estimate of the seroefficacy of a Vi-TT vaccine and shows that Typbar TCV substantially reduces the number of serologically defined (sub)clinical infections in infants, children and adults. …”

The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled,... by Kulkarni, PS, Potey, AV, Bharati, S, Kunhihitlu, A, Narasimha, B, Yallapa, S, Dharmadhikari, A, Gavade, V, Kamat, CD, Mallya, A, Sarma, AD, Goel, S, Pisal, SS, Poonawalla, CS, Venkatesan, R, Jones, E, Flaxman, A, Kim, YC, Pollard, AJ

“…The seroconversion rates on day 29 were 96·7% (95% CI 82·8–99·9) with Sii-PTCV and 100·0% (88·4–100·0) with Typbar-TCV for anti-Vi IgG; 93·3% (77·9–99·2) with Sii-PTCV and 100·0% (88·4–100·0) with Typbar-TCV for anti-Vi IgA; 100·0% (88·4–100·0) with Sii-PTCV and 3·3% (0·1–17·2) with Typbar-TCV for anti-LPS (paratyphoid); and 93·3% (77·9–99·2) with Sii-PTCV and 0% (0·0–11·6) with Typbar-TCV for SBA titres (paratyphoid). …”

Prospects of future typhoid and paratyphoid vaccines in endemic countries by Shakya, M, Neuzil, KM, Pollard, AJ

“…There are currently 2 WHO-prequalified TCVs with Typbar TCV introduced in Pakistan, Liberia, and Zimbabwe. …”

Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial by Shakya, M, Voysey, M, Theiss-Nyland, K, Colin-Jones, R, Pant, D, Adhikari, A, Tonks, S, Mujadidi, YF, O'Reilly, P, Mazur, O, Kelly, S, Liu, X, Maharjan, A, Dahal, A, Haque, N, Pradhan, A, Shrestha, S, Joshi, M, Smith, N, Hill, J, Clarke, J, Stockdale, L, Jones, E, Lubinda, T, Bajracharya, B, Dongol, S, Karkey, A, Baker, S, Dougan, G, Pitzer, VE, Neuzil, KM, Shrestha, S, Basnyat, B, Pollard, AJ

“…<br><strong> Methods<br></strong> We did a participant-masked and observer-masked individually randomised trial in Lalitpur, Nepal, in which 20 019 children aged 9 months to younger than 16 years were randomly assigned in a 1:1 ratio to receive a single dose of TCV (Typbar TCV, Bharat Biotech International, India) or capsular group A meningococcal conjugate vaccine (MenA). …”